ClinicalTrials.gg
CompletedNCT07162831MiAUpdated Nov 12, 2026

Metacognitive Intervention in Children and Adolescents With ADHD - MiA Study

An interventional study of Mio-Training in ADHD, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 1 site in Switzerland. Open to participants aged 8 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
8 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland — 5 open to participants now, 6 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Switzerland.

Enrollment
11th of 14
42 · median 80
Started
2025
with 3 others
No phase
7 of 18
3 open now
Registered
17th of 18
by date
Lead sponsor
1 of 18
Insel Gruppe AG, University Hospital Bern

Among the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, and was the 17th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 8 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of the MiA-Study is to address the current lack of effective treatment options to reduce cognitive and physical long-term problems in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Through the use of the Mio-Training, cognitive development will be strengthened and metacognitive thinking and awareness will increase.

The MiA-Study is conducted additionally to the Mio-study to evaluate the effectiveness of the Mio-Training specifically within the ADHD population.

The Mio-Training for children and adolescence with ADHD includes a combination of cognitive and coordinative training tasks and prospective as well as retrospective metacognitive questions. In a randomized controlled trial, the Mio-Training will be analysed for its efficacy on metacognitive thinking and executive functions. In particular, the investigators are interested in factors that affect the efficacy of the training program such as compliance, age, sex or the severity of the ADHD. This study will give insight into the role of metacognition in cognitive performance and will foster the development of children and adolescents with ADHD in the long-term.

Read the detailed description

In the MiA-Study, the investigators investigate a newly developed Training program at the interface between neuropsychology and sports science - the Mio-Training - for its efficacy. The aim of the Mio-Training is to strengthen the cognitive development of children and adolescents with ADHD in the long-term. The Mio-Training contains a combination of cognitive and coordinative training tasks and metacognitive questions to promote knowledge and awareness of one's own thinking. In order to counteract the shortage of skilled workers and the increasing specialization of individual specialist areas, solutions are needed that can be implemented without a lot of staff. From today's perspective, there are hardly any trainings for children and adolescents that show long-term effects on cognitive development and can also be transferred to non-trained tasks in school and everyday life.

The investigators are testing the effectiveness of the Mio-Training in a randomized clinical trial (RCT) and expect a strengthening of metacognition and core cognitive functions (i.e. executive functions). The MiA-Study will provide information about the role of metacognition in cognitive performance and, ideally, provide evidence for a novel, interdisciplinary rehabilitation strategy for children and adolescents with ADHD.

03

Conditions studied

  • ADHD

Keywords

  • Metacognition
  • ADHD
  • Cognitive training
  • Children
  • Adolescents
  • Cognitive development
04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature (see Informed Consent Form) of participants and / or one parent / legal guardian
  • Age 8-16 years
  • A diagnosis of ADHD (mild, moderate or severe)
  • Intelligence >85 (WISC-V short form)
  • German or french speaking
  • Willingness to perform the assessments without the medication (the study visits will take place without ADHD medication)

Exclusion criteria

Exclusion Criteria:

  • Any other instable neurological condition (e.g. epilepsy) that significantly impairs development
  • A severe psychiatric disease (e.g., eating disorder) or severe learning disability that significantly impairs development
  • Known or suspected non-compliance
  • Inability to follow the procedures of the study, e.g. due to language problems
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    Training group

    Training with Mio-Training for 5 weeks, three times per week.

    Behavioral: Mio-Training

  • No intervention
    Control group

    Waiting control group. Participants may use the Mio-Training after completion of the last follow-up assessment.

Interventions

  • BehavioralMio-Training

    The Mio-Training aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and coordinative skills to strenghten cognitive development in children and adolescents with ADHD.

06

What researchers measure

Primary outcomes

  1. Junior Metacognitive Awareness Inventory (Jr.MAI)

    Total score of the Junior Metacognitive Awareness Inventory over the three timepoints (baseline, immediate followup \& 3-months follow-up). Raw values ranging 18-90. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up

Secondary outcomes

  1. Wechsler Intelligence Scale For Children: 5th Ed (WISC-V)

    Indices ranging from 0 to 155. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  2. Color-Word Interference Test (Delis-Kaplan Executive Function System; D-KEFS)

    Scaled Scores ranging from 1 to 19. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  3. Tower of Hanoi (D-KEFS)

    Scaled Scores ranging from 1 to 19. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  4. Verbal learning and memory test (VLMT)

    Percentile ranks ranging from 0-100. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  5. Pattern learning (Memory and Learning Test; Basic-MLT)

    Percentile ranks ranging from 0-100. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  6. Test Battery for Attention Assessment (TAP)

    T-scores ranging from 20 to 80 (M = 50, SD = 10). Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  7. German Motor Performance Test (DMT)

    Percentile ranks ranging from 0-100. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period.

  8. Behaviour Rating Inventory of Executive Function (BRIEF)

    T-scores ranging from 20 to 80 (M = 50, SD = 10). Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up.

Other outcomes

  1. Physical Self-Description Questionnaire (PSDQ-S)

    Short version, Likert scale ranging from 1 to 6. Higher scores mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up.

  2. Conners-3 short form

    T-scores ranging from 20 to 80 (M = 50, SD = 10). Higher scores mean better outcome.

    Time frame: At baseline

  3. Questionnaire for the Assessment of Resources and Competencies in Childhood and Adolescence (FRKJ)

    Stanine rank from 1-9. Higher score mean better outcome.

    Time frame: At baseline; immediately (up to 1 week) after the training or waiting period; at 3-months follow-up.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Data can be shared upon reasonable request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Oct 2026, 14 months.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 14 months is below that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2027 → Oct 2026 and completion Aug 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 9, 2025
StartActual
Aug 1, 2025
Primary completionActual
Oct 18, 2026was Aug 2027
CompletionActual
Oct 18, 2026was Aug 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Aug 31, 2027→Oct 18, 2026 (actual)
Nov 12, 2026
Study completion
Aug 31, 2027→Oct 18, 2026 (actual)
Nov 12, 2026
Enrollment
40 (estimated)→42 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Aug 31, 2027→Oct 18, 2026 (now actual)
    Study completion Aug 31, 2027→Oct 18, 2026 (now actual)
    Enrollment 40 (estimated)→42 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07162831
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Aug 1, 2025
Primary completion
Oct 18, 2026
Completion
Oct 18, 2026
Last update
Nov 12, 2026

Study contacts

Regula Everts, Prof. Dr. phil.
principal investigator · Division of Neuropaediatrics, Development and Rehabilitation, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion